MariMed Gelecekteki Büyüme
Future kriter kontrolleri 1/6
MariMed is forecast to grow revenue at 10.7% per annum.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
n/a
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 23.7% |
Gelir büyüme oranı | 10.7% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 09 Aug 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2025 | 183 | N/A | 5 | 10 | 1 |
12/31/2024 | 164 | N/A | -6 | N/A | 1 |
6/30/2024 | 156 | -17 | -2 | 18 | N/A |
3/31/2024 | 152 | -17 | -5 | 16 | N/A |
12/31/2023 | 149 | -16 | -12 | 8 | N/A |
9/30/2023 | 146 | -1 | -10 | 6 | N/A |
6/30/2023 | 141 | 6 | -11 | 2 | N/A |
3/31/2023 | 137 | 9 | -17 | -6 | N/A |
12/31/2022 | 134 | 13 | -5 | 7 | N/A |
9/30/2022 | 129 | 2 | 0 | 13 | N/A |
6/30/2022 | 129 | 2 | 3 | 20 | N/A |
3/31/2022 | 128 | 7 | 18 | 38 | N/A |
12/31/2021 | 121 | 7 | 18 | 36 | N/A |
9/30/2021 | 111 | 18 | 15 | 30 | N/A |
6/30/2021 | 91 | 17 | 10 | 20 | N/A |
3/31/2021 | 68 | 9 | 5 | 11 | N/A |
12/31/2020 | 51 | 2 | -1 | 3 | N/A |
9/30/2020 | 36 | -80 | -5 | 2 | N/A |
6/30/2020 | 33 | -89 | -10 | -2 | N/A |
3/31/2020 | 50 | -84 | -28 | -18 | N/A |
12/31/2019 | 46 | -81 | -34 | -24 | N/A |
9/30/2019 | 44 | -10 | -34 | -26 | N/A |
6/30/2019 | 36 | -7 | -32 | -25 | N/A |
3/31/2019 | 13 | -12 | -17 | -8 | N/A |
12/31/2018 | 12 | -14 | -12 | -3 | N/A |
9/30/2018 | 10 | -7 | -19 | -2 | N/A |
6/30/2018 | 8 | -4 | -21 | 2 | N/A |
3/31/2018 | 7 | -3 | N/A | 1 | N/A |
12/31/2017 | 6 | -1 | N/A | 2 | N/A |
9/30/2017 | 6 | 0 | N/A | 3 | N/A |
6/30/2017 | 5 | 0 | N/A | 0 | N/A |
3/31/2017 | 4 | 0 | N/A | 0 | N/A |
12/31/2016 | 4 | 0 | N/A | 0 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: Insufficient data to determine if MRMD's forecast earnings growth is above the savings rate (2.5%).
Kazançlar ve Piyasa: Insufficient data to determine if MRMD's earnings are forecast to grow faster than the US market
Yüksek Büyüme Kazançları: Insufficient data to determine if MRMD's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: MRMD's revenue (10.7% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: MRMD's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if MRMD's Return on Equity is forecast to be high in 3 years time